$VCNX News

Last published 1mo ago

1mo agoVCNXSEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma StudyGlobeNewswireROCHESTER, N.Y., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. a clinical-stage biotechnology company pioneering a differentiated approach to treating Cancer and Alzheimer’s disease (AD) through the inhibition of
4mo agoVCNXVaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026GlobeNewswireROCHESTER, N.Y., July 08, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) through the inhibition of Semaphorin
10mo agoVCNXVaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer's DiseaseGlobeNewswireROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) by inhibiting semaphorin 4D
1y agoVCNXVaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual MeetingGlobeNewswireROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer's disease (AD) through the
1y agoVCNXVaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)GlobeNewswireNeoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D
1y agoVCNXVaccinex Announces Receipt of Delisting Notification from NasdaqGlobeNewswireROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative
1y agoVCNXVaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireActively Exploring Partnership for Alzheimer's DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company
2y agoVCNXVaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITCGlobeNewswireROCHESTER, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the
2y agoVCNXVaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual MeetingGlobeNewswireROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease (NDD)
2y agoVCNXVaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, SpainGlobeNewswireROCHESTER, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vaccinex (NASDAQ:VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease. Vaccinex
2y agoVCNXVaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024GlobeNewswireROCHESTER, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) and cancer through the
2y agoVCNXVaccinex Announces Exercise of Warrants for $6.2 Million in Gross ProceedsGlobeNewswireROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative
2y agoVCNXVaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development PartnershipGlobeNewswireROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (NASDAQ:VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease. Our Company
2y agoVCNXVaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's DiseaseGlobeNewswireResults affirm expectation of a novel mechanism of action targeting astrocyte activation to delay progression of Alzheimer's disease from early stage Mild Cognitive Impairment Findings echo previous phase 2 results in
2y agoVCNXVaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease at the Alzheimer's Association International Conference, Philadelphia, July 31, 2024GlobeNewswireROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) and cancer through the
2y agoVCNXVaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's DiseaseGlobeNewswireCompany expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation,believed to be key drivers of neurodegeneration.
2y agoVCNXVaccinex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireLast patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer's Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex,
2y agoVCNXVaccinex Reports 2023 Financial Results and Provides Corporate UpdateGlobeNewswireExpect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer's Disease in Q3 2024 Company raised $17.9 million of new financing during Q4 2023 and Q1 2024 ROCHESTER, N.Y., April 02, 2024
2y agoVCNXVaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswireROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's
2y agoVCNXVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyGlobeNewswireEight new antibody discovery agreements incorporate Vaccinex's powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against challenging
2y agoVCNXVaccinex, Inc. Announces Reverse Stock SplitGlobeNewswireROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the
2y agoVCNXVaccinex Announces Pricing of $3.7 Million PIPE FinancingGlobeNewswireROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative
2y agoVCNXNasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing RuleGlobeNewswireCompany Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer's Disease on Schedule to Complete Treatment in June 2024 ROCHESTER, N.Y., Dec. 04,
2y agoVCNXVaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer's Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new financing during Q3 and
3y agoVCNXVaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual MeetingGlobeNewswireROCHESTER, N.Y., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company, will be reporting novel findings for its lead product, pepinemab, in two presentations at the
3y agoVCNXVaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative DiseasesGlobeNewswireROCHESTER, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company, today reports novel findings for its lead product, pepinemab, in a highlighted podium
3y agoVCNXVaccinex Announces Pricing of $9.6 Million Public OfferingGlobeNewswireROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative
3y agoVCNXVaccinex's Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept CollaborationGlobeNewswireApplication is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their "native conformation" so as to efficiently induce and select specific
3y agoVCNXVaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® ApplicationGlobeNewswirePhase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be reviewed on September 28 at CHI's 20th Annual Discovery on Target (DOT)
3y agoVCNXVaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and CancerGlobeNewswire"Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease" will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimer's Disease Conference to be
3y agoVCNXVaccinex, Inc. Announces Reverse Stock SplitGlobeNewswireROCHESTER, N.Y., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through
3y agoVCNXVaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer's Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer
3y agoVCNXVaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ETGlobeNewswireROCHESTER, N.Y., June 01, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the
3y agoVCNXVaccinex Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireSignificant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 (GLOBE NEWSWIRE) -- Vaccinex,
3y agoVCNXVaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer's Disease) Study of PepinemabGlobeNewswireTopline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington's Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a
3y agoVCNXVaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian CellsGlobeNewswireGPCRs play a key role in many important physiological processes which makes them an important class of drug targets; however, their biophysical properties have made many GPCRs "difficult to drug" New technology makes it
3y agoVCNXVaccinex Announces Private Placement with Commitments of $5.0 MillionGlobeNewswireROCHESTER, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative
3y agoVCNXVaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical ProgramsGlobeNewswireExpect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer's study in April 2023 with topline data anticipated mid-2024 Completed enrollment of 36 patients required for a pre-planned
3y agoVCNXVaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity ConferenceGlobeNewswireROCHESTER, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX, "Vaccinex")), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and
3y agoVCNXVaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)GlobeNewswireThe study is intended to assess whether pepinemab can reverse the suppressive tumor microenvironment found in PDAC, thereby facilitating the anti-tumor activity of immune checkpoint blockade This
3y agoVCNXVaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim AnalysisGlobeNewswireInterim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks after initiating treatment The open-label Phase 1b/2 KEYNOTE B-84 study is evaluating the
3y agoSURF VCNXVaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface OncologyGlobeNewswireROCHESTER, N.Y., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the
3y agoVCNXVaccinex Announces $3.8 Million Private PlacementGlobeNewswireROCHESTER, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the
3y agoVCNXVaccinex Reports Third Quarter 2022 Results and Provides Corporate UpdateGlobeNewswirePromising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patient enrollment continues in the Phase 1b/2
4y agoVCNXVaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of CancerGlobeNewswireROCHESTER, N.Y., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative diseases through the
4y agoVCNXVaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical ProgramsGlobeNewswirePromising initial responses in continuing Phase 1b/2 KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Phase 2 SIGNAL-HD Study Published in Nature Medicine Patient enrollment continues in
4y agoVCNXVaccinex, Inc.'s Phase 2 "SIGNAL" Study to Evaluate Pepinemab Antibody in Huntington's Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of NeuroinflammationGlobeNewswireData suggest that pepinemab slows or prevents cognitive decline in Huntington's Disease (HD) Results highlight the potential for impact on other neurodegenerative and neuroinflammatory diseases including Alzheimer's ROCHESTER, N.Y., Aug. 08, 2022
4y agoVCNXVaccinex, Inc. Announces Presentation at the 2022 Alzheimer's Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer's DiseaseGlobeNewswireROCHESTER, N.Y., July 29, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announ
4y agoVCNXVaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ETGlobeNewswireROCHESTER, N.Y., May 25, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announc
4y agoVCNXVaccinex Reports First Quarter 2022 Results and Provides Corporate UpdateGlobeNewswireExcellent Progress in Pepinemab Clinical Programs Promising responses in Phase 1b segment of the open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC);Phase 2 enrollment und